Response of serum carboxylated and undercarboxylated osteocalcin to risedronate monotherapy and combined therapy with vitamin K2 in corticosteroid-treated patients: A pilot study

Internal Medicine

Volumn 49, Issue 5, 2010, Pages 371-376

  Hozuki, Takayoshi ^a   Imai, Tomihiro ^a   Tsuda, Emiko ^a   Matsumura, Akihiro ^a   Yamamoto, Daisuke ^a   Toyoshima, Takanobu ^a   Suzuki, Syuuichiro ^a   Yamauchi, Rika ^a   Hayashi, Takashi ^a   Hisahara, Shin ^a   Shimohama, Shun ^a  

^a SAPPORO MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Corticosteroid; N terminal telopeptide of type I collagen; Osteocalcin; Risedronate; Undercarboxylated osteocalcin; Vitamin K2

Indexed keywords

AMINO TERMINAL TELOPEPTIDE; CORTICOSTEROID; FARNOQUINONE; OSTEOCALCIN; RISEDRONIC ACID; STEROID;

ADULT; AGED; ARTICLE; CARBOXYLATION; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; MALE; MONOTHERAPY; NEUROMUSCULAR DISEASE; PILOT STUDY; TREATMENT RESPONSE; VITAMIN SUPPLEMENTATION;

ADRENAL CORTEX HORMONES; ADULT; AGED; BIOLOGICAL MARKERS; BONE AND BONES; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; COLLAGEN TYPE I; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; ETIDRONIC ACID; FEMALE; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; NEUROMUSCULAR DISEASES; OSTEOCALCIN; PEPTIDES; PILOT PROJECTS; PREDNISOLONE; TREATMENT OUTCOME; VITAMIN K 2;

EID: 77749340770     PISSN: 09182918     EISSN: 13497235     Source Type: Journal    
DOI: 10.2169/internalmedicine.49.2551     Document Type: Article

References (41)

1. 2 modulates proliferation and function of osteoblastic cells in vitro. Biochem Biophys Res Commun 187: 814-820, 1992.
2. Price PA. Vitamin K-dependent formation of bone Gla protein (osteocalcin) and its function. Vitam Horm 42: 65-108, 1985.
3. 2 in postmenopausal women. J Bone Miner Metab 26: 260-264, 2008.
4. 2 (menatetrenone) on bone metabolism in postmenopausal women. Endocrine J 49: 363-370, 2002.
5. Nakashima A, Yorioka N, Doi S, Masaki T, Ito T, Harada S. Effects of vitamin K2 in hemodialysis patients with low serum parathyroid hormone levels. Bone 34: 579-583, 2004.
6. 2 (menatetrenone) effectively prevents fractures and sustains lumbar bone mineral density in osteoporosis. J Bone Miner Res 15: 515-521, 2000.
7. Gennari C. Glucocorticoids and bone. In: Bone and Mineral Research. Vol. 3. Peck WA, Ed. Excepta Medica, Amsterdam, 1998: 213-231.
8. Lukert BP, Raisz LG. Glucocorticoid-induced osteoporosis: Pathogenesis and management. Ann Intern Med 112: 352-364, 1990.
9. Hara K, Akiyama Y, Ohkawa I, Tajima T. Effects of menatetrenone on prednisolone-induced bone loss in rats. Bone 14: 813-818, 1993.
10. 2 (menatetrenone) inhibits bone loss induced by prednisolone partly through enhancement of bone formation in rats. Bone 31: 575-581, 2002.
11. Nawata H, Soen S, Takayanagi R, et al. Guidelines on the management and treatment of glucocorticoid-induced osteoporosis of the Japanese society for bone and mineral research (2004). J Bone Miner Metab 23: 105-109, 2005.
12. Godshalk MF, Downs RW. Effect of short-term glucocorticoids on serum osteocalcin in healthy young men. J Bone Miner Res 3: 113-115, 1988.
13. Ton FN, Gunawardene SC, Lee H, Neer RM. Effects of low-dose prednisolone on bone metabolism. J Bone Miner Res 20: 464-470, 2005.
14. Hauschka PV, Lian JB, Gallop PM. Direct identification of the calcium-binding amino acid, gamma-carboxyglutamate, in mineralized tissue. Proc Natl Acad Sci USA 72: 3925-3929, 1975.
15. Price PA, Pose JW, Raman N. Primary structure of γ-carboxyglutamic acid-containing protein from bovine bone. Proc Natl Acad Sci USA 73: 3374-3375, 1976.
16. Delmas PD. Biochemical markers of bone turnover. I: Theoretical considerations and clinical use in osteoporosis. Am J Med 95: 11 S-16S, 1993.
17. Price PA, Williamson MK, Lothringer JW. Origin of the vitamin K-dependent bone protein found in plasma and its clearance by kidney and bone. J Biol Chem 256: 12760-12766, 1981.
18. Bitensky L, Hart JP, Catterall A, Hodges SJ, Pilkington MJ, Chayen J. Circulating vitamin K levels in patients with fractures. J Bone Jt Surg Br 70: 663-664, 1988.
19. 1 in osteoporosis. J Clin Endocrinol Metab 60: 1268-1269, 1985.
20. Hodges SJ, Pilkington MJ, Stamp TCB, et al. Depressed levels of circulating menaquinones in patients with osteoporotic fractures of the spine and femoral neck. Bone 1: 387-389, 1991.
21. 2 decreased in elderly women with hip fracture. J Bone Miner Res 8: 1241-1245, 1993.
22. Liu G, Peacock M. Age-related changes in serum undercarboxylated osteocalcin and its relationships with bone density, bone quality, and hip fracture. Calicif Tissue Int 62: 286-289, 1998.
23. Luukinen H, Kakonen SM, Pettersson K, et al. Strong prediction of fractures among older adults by the ratio of carboxylated to total serum osteocalcin. J Bone Miner Res 15: 2473-2478, 2000.
24. Plantalech L, Guillaumont M, Vergnaud P, Leclerocq M, Delmas PD. Impairment of gamma carboxylation of circulating osteocalcin (bone Gla protein) in elderly women. J Bone Miner Res 6: 1211-1216, 1991.
25. Szulc P, Chapuy M, Meunier PJ, Delmas PD. Serum undercarboxylated osterocalcin is a marker of the risk of hip fracture in elderly women. J Clin Invest 91: 1769-1774, 1993.
26. Vergnaud P, Garnero P, Meunier PJ, Breart G, Kamihagi K, Delmas PD. Undercarboxylated osteocalcin measured with a specific immunoassay predicts hip fracture in elderly women. J Clin Endocrinol Metab 82: 719-724, 1997.
27. Obrant KJ, Kakonen SM, Astermark J, et al. The proportion of carboxylated to total or intact osteocalcin in serum discriminates warfarin-treated patients from control subjects. J Bone Miner Res 14: 555-560, 1999.
28. Bressot C, Meunier PJ, Chapuy MC, LeJeune E, Edouard C, Darby AJ. Histomorphometric profile, pathophysiology and reversibility of corticosteroid-induced osteoporosis. Metab Bone Dis Rel Res 1: 303-311, 1979.
29. Jowsey J, Riggs BL. Bone formation in hypercortisonism. Acta Endocrinol 63: 21-28, 1970.
30. Meunier PJ, Dempster D, Edouard C, Chapuy MC, Arlot M, Charhon P. Bone histomorphometry in corticosteroid-induced osteoporosis and Cushing's syndrome. Adv Exp Med Biol 171: 191-200, 1984.
31. 2 (menaquinone 4) reduces serum undercarboxylated osteocalcin level as early as 2 weeks in elderly women with established osteoporosis. J Bone Miner Metab 21: 161-165, 2003.
32. Wallach S, Cohen S, Reid DM, et al. Effects of risedronate treatment on bone density and vertebral fracture in patients on corticosteroid therapy. Calcif Tissue Int 67: 277-285, 2000.
33. Majima T, Shimatsu A, Komatsu Y, et al. Effects of risedronate or alfacalcidol on bone mineral density, bone turnover, back pain, and fractures in Japanese men with primary osteoporosis: results of two-year strict observational study. J Bone Miner Metab 27: 168-174, 2009.
34. Takada J, Iba K, Yamashita T. Changes in bone resorption markers among Japanese patients with postmenopausal osteoporosis treated with alendronate and risedronate. J Bone Miner Metab 25: 142-146, 2007.
35. Eastell R, Mallinak K, Weiss S, et al. Biological variability of serum and urinary N-telopeptides of type I collagen in postmenopausal women. J Bone Miner Res 15: 594-598, 2000.
36. Montagnani A, Gonnelli S, Cepollaro C, et al. A new serum assay to measure N-terminal fragment of telopeptide of type I collagen in patients with renal osteodystrophy. Eur J Intern Med 14: 172-177, 2003.
37. Khosla S, Melton III LJ. Corticosteroid-induced osteoporosis. In: Osteoporosis, Etiology, Diagnosis and Management. 2nd ed. Riggs BL, Melton III LJ, Eds. Lippincott-Raven, Philadelphia, 1995: 185-189.
38. Chenu C, Colucci S, Grano M, et al. Osteocalcin induces chemotaxis, secretion of matrix proteins, and calcium-mediated intracellular signaling in human osteoclast-like cells. J Cell Biol 127: 1149-1158, 1994.
39. 2 (menatetrenone) on bone resorption may be related to its side chain. Bone 16: 179-184, 1995.
40. Kameda T, Miyazawa K, Mori Y, et al. Vitamin K2 inhibits osteoclastic bone resorption by inducing osteoclast apoptosis. Biochem Biophys Res Commun 220: 515-519, 1996.
41. Booth SL, Dallal G, Shea MK, Gundberg C, Peterson JW, Dawson-Hughes B. Effects of vitamin K supplementation on bone loss in elderly men and women. J Clin Endochrinol Metab 93: 1217-1223, 2008.